Greg Bodulovic

Greg Bodulovic is a distinguished partner at DLA Piper in Sydney, specialising in intellectual property law with an extensive academic background in biotechnology. Greg's expertise encompasses both contentious and non-contentious aspects of intellectual property, with a keen focus on the regulation of therapeutic goods in Australia. His legal acumen is evident in his representation in patent infringement and revocation proceedings before the Federal Court and High Court of Australia, as well as patent opposition matters before the Australian Patent Office. Greg has successfully acted in design, trade mark, and copyright infringement cases, showcasing his ability to manage complex legal disputes. He has played a pivotal role in handling significant patent litigation for a multinational pharmaceutical company in groundbreaking cases involving claims on undertakings as to damages, setting precedents in pharmaceutical patent litigation. His recognitions include prestigious mentions in IAM Patent 1000, Legal 500 Asia-Pacific, and World Trademark Review, reflecting his status as a notable practitioner in the field. Before joining DLA Piper, Greg held prominent positions at Jones Day and Griffith Hack, where he advised on a wide range of non-contentious intellectual property matters, from drafting commercial agreements to managing intellectual property due diligence. Greg holds an LLB (Honours) in Law, a Bachelor of Science in Chemistry, Biology, and Biotechnology, and a Master of Philosophy in Biotechnology from The Australian National University. His contributions to DLA Piper's life sciences publications further illustrate his commitment to the ever-evolving field of intellectual property law.